Mercator Therapeutics and Pepscan Establish Research and Licensing Collaboration

Published: Jan 03, 2011

WALTHAM, Mass. & LELYSTAD, the Netherlands--(BUSINESS WIRE)--Mercator Therapeutics, the first biopharmaceutical company to systematically use in vivo phage display technology to develop novel cancer drugs and Pepscan Therapeutics, a world leader in protein mimicry technologies for improved therapeutic peptides and anti-GPCR antibodies, today announced a multi-program research collaboration. The companies will collaborate to optimize Mercator’s ‘Homing Peptides’ using Pepscan’s proprietary CLIPS technology.

Back to news